Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC) (REGISTEM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02819882
Recruitment Status : Recruiting
First Posted : June 30, 2016
Last Update Posted : December 3, 2020
Sponsor:
Collaborators:
Hoffmann-La Roche
Novartis
AstraZeneca
Pfizer
Celgene
Information provided by (Responsible Party):
Spanish Breast Cancer Research Group

Brief Summary:
This study is a prospective, multicenter non-interventional cohort study designed to develop a registry in unresectable locally advanced or metastatic disease.

Condition or disease Intervention/treatment
Breast Neoplasms Other: No intervention

Detailed Description:

The target population for inclusion in this study is breast cancer patients recently diagnosed (from January 2016) with unresectable locally advanced or metastatic disease (either after a recurrence or as first diagnosis). No treatment regimen will be protocol specified. This is an observational study in which clinical decisions concerning the optimum management strategy for a particular patient are taken independently of and/or prior to, any decision by the physician to invite a patient to participate in the study. The treating physician will make all treatment decisions according to his/her regular clinical practice independent of this study. Patients enrolled on the study are free to withdraw their informed consent for the use and disclosure of health information at any time and when asked, patients are not obliged to provide a reason. Patients may request discontinuation from the study at any time.

The date and the reason for withdrawal or discontinuation from the study must be recorded in the electronic case report form (eCRF). An attempt will be made to determine the date of discontinuation and final status (i. e. withdrawal of consent, loss to follow-up, death) of any patient who discontinues from the study. However, the treating clinician is encouraged to follow the patient as long as possible, until patient death or through study end. The Sponsor has the right to terminate the study at any time. The Sponsor will notify the investigator if the study is placed on hold or if the Sponsor decides to discontinue the study.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 1400 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 5 Years
Official Title: A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)
Actual Study Start Date : August 2016
Estimated Primary Completion Date : June 2024
Estimated Study Completion Date : June 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Group/Cohort Intervention/treatment
Luminal A-like subtype
Patients that express Estrogen receptor (ER), express Progesterone Receptor (PgR)+ (≥ 20%), don't express HER2 and have Ki-67 'low' (< 14%).
Other: No intervention
Luminal B-like (HER2 negative) subtype:
Patients that express ER and are either PgR- or low (< 20%) and/or Ki67 'high' (≥ 14%).
Other: No intervention
Luminal B-like (HER2 positive) subtype:
Patients that express ER and HER2 irrespective of PgR or Ki67 status.
Other: No intervention
HER2-enriched subtype
Patients that express HER2 and don't express ER or PgR.
Other: No intervention
Triple Negative (TN) subtype
Patients who are negative for the expression of ER, PgR and HER2.
Other: No intervention



Primary Outcome Measures :
  1. Number of patients with the different breast cancer subtypes and real distribution of them. [ Time Frame: 8 years ]
    Number of patients with the different breast cancer subtypes (Luminal A-like, Luminal B-like [HER2 negative], Luminal B-like [HER2 positive], HER2-enriched and Triple Negative) of the unresectable locally advanced or metastatic disease


Secondary Outcome Measures :
  1. Breast cancer and heredofamiliar risk according with the patient and tumor characteristics. [ Time Frame: 8 years ]
    It will be performed a table with patient and tumor characteristics including only those patients with heredofamiliar risk.

  2. Differences in the development disease in the group of male vs female patients. [ Time Frame: 8 years ]
    It will be performed an analysis separately for each subtype and by male and female and it will analyse if there are any significative difference between them.

  3. Overall trends in outcomes by breast cancer subtypes. [ Time Frame: 8 years ]
    Progression Free Survival (PFS), Overall Survival (OS) and Death will be evaluated between the different cancer subtypes. We will evaluate the prognostic relevance of the intrinsic subtypes.

  4. Influence of primary tumor surgery in patient outcomes [ Time Frame: 8 years ]
    Progression Free Survival (PFS), Overall Survival (OS) and Death will be evaluated considering the type of surgery of the primary tumor.

  5. Influence of timing of primary tumor surgery in patients with metastatic disease as first diagnosis [ Time Frame: 8 years ]
    Influence of timing of primary tumor surgery in patients with metastatic disease as first diagnosis

  6. Influence of local therapy (surgery, radiotherapy and radiofrequency) in the outcome of patients with oligometastatic disease [ Time Frame: 8 years ]
    PFS, OS and Death will be evaluated in with oligometastatic disease and with or without local therapy.

  7. Prevalence (at entry) and incidence (during the observation period) of pregnancies, abortions and pregnancy outcomes. [ Time Frame: 8 years ]
    Number of patients pregnant, number of patients pregnant with abortions, and pregnancy outcomes.

  8. Number of participants with specific biomarkers on tumor and blood samples. [ Time Frame: 8 years ]
    to improve the understanding of metastatic breast cancer by performing analysis on tumor and blood samples.

  9. IHC/ISH discrepancies between the primary tumor and the metastasis in patients with biopsy of the metastatic lesions. [ Time Frame: 8 years ]
    It will be performed a comparison between the Immunohistochemistry (IHC)/ In Situ Hybridization (ISH) characteristics of the primary tumor and the metastatic lesion(s).


Biospecimen Retention:   Samples With DNA
Blood samples Primary and metastatic lesion tissue samples


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The target population for inclusion in this study is breast cancer patients recently diagnosed (from January 2016) with unresectable locally advanced or metastatic disease (either after a recurrence or as first diagnosis).
Criteria

Inclusion Criteria:

  1. Patients (males or females) diagnosed with unresectable locally advanced or MBC (either after a recurrence or as first diagnosis) from January 2016.
  2. Able and willing to provide written informed consent.
  3. Age ≥ 18 years.
  4. Availability to medical records access and all data related to the disease management.

Exclusion Criteria:

None


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02819882


Contacts
Layout table for location contacts
Contact: MS Study Project Manager +34 916892870 inicio_ensayos@geicam.org
Contact: Start-Up Unit Manager +34 916892870 inicio_ensayos@geicam.org

Locations
Show Show 40 study locations
Sponsors and Collaborators
Spanish Breast Cancer Research Group
Hoffmann-La Roche
Novartis
AstraZeneca
Pfizer
Celgene
Investigators
Layout table for investigator information
Study Director: Study Director Hospital Universitario Fundación Alcorcón, Madrid
Study Director: Study Director Hospital de Donostia, San Sebastián
Study Director: Study Director Hospital Universitario Gregorio Marañón, Madrid
Study Director: Study Director Hospital Universitario Reina Sofía,Córdoba
Additional Information:
Layout table for additonal information
Responsible Party: Spanish Breast Cancer Research Group
ClinicalTrials.gov Identifier: NCT02819882    
Other Study ID Numbers: GEICAM 2014-03
First Posted: June 30, 2016    Key Record Dates
Last Update Posted: December 3, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Spanish Breast Cancer Research Group:
Unresectable
locally
advanced
metastatic disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases